Clinical Trial Update: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) [Phase 3]

View source ↗

Summary

A Phase 3 Japan study evaluating subcutaneous immunoglobulin for patients with primary immune deficiency requiring IgG replacement therapy, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin) (immunoglobulin G, subcutaneous)

Snippet

Sponsor: CSL Behring | Conditions: Primary Immune Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2013-03-20